2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
04:00 p.m. - 05:30 p.m.
MCCNO - Hall B
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, (CAR)-T Cell Therapies, Immunotherapy, Biological Processes, Apoptosis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Research, Translational Research, Study Population, Animal Model
PAPER

361 Leukemia stem cells require polyamine-dependent synthesis of the mitochondrial translation regulator RMND1 for survival.

Karina Elizabeth Jimenez Camacho, PhD, Yun Chueh2, Nha-Nhu Le3, Adrianna Cepa, MSc4, Raveen Stephen Stallon Illangeswaran5, Paula Saez-Raez6, Christina Sexton7, Katherine Carter8, Cody Stillwell9, Andrea Arruda10, Dan A. Pollyea11, Craig Jordan, PhD12, Mark Wunderlich, Manager13, Julie A Reisz Haines, PhD14, Monika Dzieciatkowska, PhD15, Anit Tyagi16, Mike Adam17, Nathan Salomonis, PhD18, Angelo D'Alessandro, PhD19, Courtney L. Jones, PhD20
1 Advanced Leukemia Therapies and Research Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati Cancer Center, Cincinnati, United States
2 Advanced Leukemia Therapies and Research Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
3 Advanced Leukemia Therapies and Research Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
4 Advanced Leukemia Therapies and Research Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
5 Advanced Leukemia Therapies and Research Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati Cancer Center, Cincinnati, United States
6 Advanced Leukemia Therapies and Research Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, University of Cincinnati Cancer Center, Cincinnati, United States
7 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
8 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
9 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
10 Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
11 Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, United States
12 Division of Hematology, Department of Medicine, University of Colorado School of Medicine, Aurora, Colorado, United States
13 Advanced Leukemia Therapies and Research Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
14 Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
15 Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
16 Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
17 Advanced Leukemia Therapies and Research Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
18 Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, United States, Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, United States, University of Cincinnati Cancer Center, Cincinnati, United States
19 Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
20 Advanced Leukemia Therapies and Research Center, Cincinnati, Ohio, United States, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States, Department of Pediatrics, University of Cincinnati, Cincinnati, Ohio, United States, University of Cincinnati Cancer Center, Cincinnati, United States

Acute myeloid leukemia (AML) exhibits high relapse rates driven by therapy‑resistant leukemia stem cells (LSCs), which rely on oxidative phosphorylation (OXPHOS) and polyamine metabolism for survival. Spermidine regulates protein synthesis through hypusination of eukaryotic translation initiation factor 5A (eIF5A), a modification required for efficient translation of poly‑proline rich proteins. Although polyamine depletion shows therapeutic promise in AML, the mechanisms supporting AML cell survival remain incompletely defined.

Using the polyamine‑targeting agent N1, N11-diethylnorspermine (DENSpm) and eIF5A hypusination inhibitor GC7 in 11 primary AML specimens and two patient-derived xenograft (PDX) models, we observed reduced eIF5A-hypusination, decreased protein synthesis, and impaired colony‑forming capacity, with DENSpm completely abolishing clonogenic growth and GC7 significantly reducing colony formation. In contrast, normal CD34⁺ bone marrow cells were largely unaffected, indicating selective impairment of leukemic progenitor cells. RNA‑sequencing revealed strong negative enrichment of mitochondrial translation, respiratory complex assembly, ATP synthesis and OXPHOS pathways. Similar transcriptional changes occurred in reactive oxygen species (ROS)-low LSC-enriched populations from five primary AML specimens but were absent in normal hematopoietic stem and progenitor cells (HSPCs), highlighting an LSC-specific vulnerability. Functional validation using Seahorse assays demonstrated reduced oxygen consumption rates, basal respiration and ATP production in both primary AML specimens and PDX models following polyamine depletion, while mitochondrial respiration in normal CD34+ bone marrow cells was unaffected. These findings indicate an AML-specific role for polyamines in regulating mitochondrial respiration.

To identify the mechanism by which polyamine‑dependent hypusination controls mitochondrial metabolism, we performed proteomics in ROS-low LSC-enriched populations from 11 AML specimens treated with DENSpm and GC7. RMND1, a mitochondrial protein required for anchoring mRNA to the mitoribosome and essential for the translation of OXPHOS enzymes, was consistently downregulated under both conditions, which was validated by western blotting in primary AML specimens and PDX models. Notably, RMND1 has not been previously linked to polyamine metabolism or AML biology.

To assess translational regulation of RMND1, we performed ribosome profiling in PDX models following DENSpm and GC7 treatment. RMND1 showed a marked reduction in translation efficiency, establishing it as a polyamine‑dependent translational target. Pathway analysis of ribosome profiling data further defined suppression of mitochondrial translation and respiratory complex assembly programs, reinforcing a mechanistic link between polyamine depletion and mitochondrial dysfunction in AML.

We next investigated whether RMND1 is functionally required for AML cell survival. Knockdown of RMND1 using four independent shRNAs in two PDX models resulted in complete ablation of clonogenic potential, whereas RMND1 knockout did not affect the colony-forming capacity of G-CSF-mobilized CD34⁺ cells. Seahorse assays revealed significant reductions in OXPHOS, basal respiration and ATP production following RMND1 depletion. Genetic targeting of RMND1 impaired leukemic engraftment and improved mouse survival, demonstrating that RMND1 is essential for AML progenitor activity in vivo. RNA-seq analysis of RMND1-depleted AML cells recapitulated the transcriptional suppression of mitochondrial translation, mitochondrial complex assembly, ATP synthesis and OXPHOS pathways observed with polyamine depletion. These data identify RMND1 as a novel target in AML and LSCs.

Finally, to determine whether RMND1 mediates the effects of polyamine depletion, we overexpressed RMND1 in two PDX models. RMND1 overexpression rescued colony formation and mitochondrial respiration following DENSpm and GC7 treatment. Moreover, RMND1-overexpressing cells retained leukemic engraftment following ex vivo DENSpm treatment, demonstrating that reduced RMND1 expression is responsible for decreased leukemia stem and progenitor cell (LSPC) function upon polyamine depletion.

Together, these findings identify RMND1 as a polyamine-dependent regulator of mitochondrial translation, essential for AML LSC function. Our work establishes the polyamine-eIF5A-RMND1 axis as a therapeutic vulnerability in AML.

Karina Elizabeth Jimenez Camacho, PhD: No relevant conflicts of interest to declare.